Sign up Australia
Proactive Investors - Run By Investors For Investors

The Hydroponics Company to sell unique lighting products for the cannabis market

This exclusive distribution contract adds to the portfolio of products marketed in Canada.
a cannabis farm
The new products allow lighting to be regulated

The Hydroponics Company Ltd’s (ASX:THC) Canada-based subsidiary, Crystal Mountain-Dragon Vision (CMDV) will start selling Nanolux Technology’s products in Canada.

Nanolux is a manufacturer of lighting and ballasts for the hydroponic market, with sales in excess of $100 million and distribution to over 600 retailers throughout the U.S.

This exclusive distribution contract adds to the portfolio of products currently marketed by CMDV to the rapidly growing Canadian marketplace for cannabis growth and production.

READ: The Hydroponics Company raises $8 million to fast-track development of medicinal cannabis in Australia

Nanolux products allow lighting to be regulated in order to optimise growing conditions through a unique cloud based control system.

Importantly, users can monitor and control their entire facility from anywhere in the world from an Apple or Android device using the NCCS App.

David Radford, chief executive officer, said: “The addition of this new range of lighting products to CMDV’s hydroponic portfolio is a significant step forward in the execution of THC’s growth strategy for Canada.”

The Hydroponics Company is aiming to build its business organically by adding new agencies to its portfolio while advancing discussions with several acquisition targets.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full THC profile View Profile

Hydroponics Company Ltd Timeline

Related Articles

Laboratory
June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India
Lung X-Ray
October 08 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use